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doi:10.1016/j.ejvs.2008.02.006Abstract Introduction: PET-FDG and USPIO-enhanced MRI are increasingly being used in de-
picting carotid atheroma inflammation e a risk factor for the high risk plaque. Their combined
use has not been previously reported.
Report: Two patients presenting with stroke and identified with 50% carotid stenosis on duplex
ultrasonography, underwent PET FDG and USPIO-enhanced MR imaging. Results were concor-
dant and complementary suggesting that both techniques reflect similar metabolic processes.
Discussion: The selection of patients for carotid revascularisation has largely been based on
the severity of luminal stenosis alone. The two imaging modalities, which identify inflamma-
tory activity, may be potential surrogate risk markers in the selection of patients eligible
for carotid surgery, if plaque inflammation can be correlated with risk of developing clinical
symptoms.
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ty for Vascular Surgery. PublisheIntroduction
Appreciation of the inflammatory nature of the atheroscle-
rotic process has prompted the need for non-invasive
characterization of the metabolic and functional state of
atherosclerotic plaques in vivo. Positron emission tomogra-
phy with 18F-Fluorodeoxyglucose (PET FDG) and high-
resolution magnetic resonance imaging (MRI) using
ultrasmall superparamagnetic iron oxide (USPIO) particlesd by Elsevier Ltd. All rights reserved.
54 T.Y. Tang et al.(Sinerem, Guerbet, France) have both emerged as promis-
ing techniques to address this in the carotid circulation.1 We
report, for the first time, on using both modalities in two
symptomatic patients with moderate carotid artery disease.
Case Report 1
A 76-year-old man experienced several brief episodes of
right upper limb weakness, visual disturbance and speech
difficulty over two weeks, consistent with a transient
ischaemic attack. The only known vascular risk factor was
essential hypertension. Duplex ultrasonography revealed
a left 55% carotid stenosis. Brain MRI revealed a recent
left frontal infarction. He was started on aspirin and
atorvastatin. The dysphasia resolved completely over the
subsequent two weeks but the patient suffered a further
right-sided hemiparesis just prior to his planned left carotid
endarterectomy.
An initial high-resolution MRI of the neck (imaging
parameters on request), performed 2 weeks after pre-
sentation, showed an eccentric plaque in the left ICA
(Fig. 1). PET FDG performed on the same day (acquired in
3D-mode for 75 minutes after injection of 185 MBq FDG;
GE PET Advance scanner) showed increased uptake of the
tracer into the plaque (SUVmax 3.6). USPIO enhanced MR
imaging was also acquired using a quadruple inversion
recovery spiral 2D T2*W sequence, pre and 36 hours post
intravenous administration of Sinerem, and showed a drop
in signal intensity within the plaque indicating uptake of
USPIO and likely inflammatory activity. MR images wereFigure 1 Axial MRI and PET scans of the neck in patient 1 showin
and corresponding high uptake of FDG into the plaque (C & D: blu
artery (C & D: purple arrows). In patient 2, no change of MRI signal
increased FDG uptake are seen in the right ICA plaque (G & H: gremanually co-registered according to plaque morphology
and distance from the carotid bifurcation at the time of
imaging.
Case Report 2
A 59-year-old man presented with a right amaurosis fugax.
He had been a heavy smoker for 25 years. MRI of the brain
showed some evidence of small vessel disease. He was
found to have a right 50% ICA stenosis on duplex ultraso-
nography. He was started on aspirin and atorvastatin and
remains symptom free.
Three weeks after the onset of symptoms, high-
resolution MRI of the neck showed a concentric plaque in
the right ICA (Fig. 1). Sinerem-enhanced MRI and PET FDG
performed within a week of the initial MRI showed no
change in signal intensity between pre and post USPIO
imaging and no significant uptake of the tracer respectively
into the plaque.
Both patients did not experience any side effects from
either the tracer or USPIO infusion.
Discussion
In both of these cases, moderate carotid disease was
identified on ultrasonography and assumed to be the culprit
lesions. Current evidence from large clinical trials (based
solely on luminal narrowing) suggests that a stenosis of 50%
represents a rather grey area in terms of the decision ofg signal loss after USPIO administration (B: yellow arrow heads)
e arrows). Note also high uptake in the contralateral vertebral
between pre and post-USPIO scans (E & F: green arrows) and no
en arrows).
PET and Contrast Enhanced-MR in Carotid Artheroma Imaging 55carotid endarterectomy with wide variation in clinical
practice.2 The detailed structural and functional informa-
tion provided by MRI and PET may aid in making this deci-
sion. In patient 1, remodelling of the ICA had
accommodated the large plaque, which might have other-
wise warranted surgical intervention. Functionally, both
PET FDG and MRI USPIO suggest high inflammatory activity
within the plaque in patient 1, but not in patient 2. It is
interesting to note that patient 1 developed recurrent
symptoms as well. The agreement in defining the metabolic
status of the plaque is very encouraging and gives further
strength to the evidence that both modalities reflect simi-
lar aspects of the atherosclerotic process, namely, macro-
phage recruitment and activation. The apparent
quiescence of the plaque in the second patient may be
attributed to (i) the lag between symptoms and imaging
and the use of a statin, both possibly allowing stabilization
of the inflammatory process (although the sequence of
events is similar to patient 1) or (ii) that indeed the plaque
was not the culprit in this case.
USPIO-enhanced MRI has been used to demonstrate
macrophage activity in symptomatic human carotid pla-
ques3 and whilst the tool appears useful, imaging relies on
areas of signal loss making quantification difficult. More-
over imaging has to be repeated within 36 hours, thus add-
ing impracticability. PET FDG with its associated radiation
burden limits the number of PET scans that patients can
undertake. Accurate quantification, however, is possible
when used in conjunction with MRI or computed tomogra-
phy, despite being time- and labour-intensive and having
limited spatial resolution.4
There is an increasing desire to formulate surrogate
endpoints for clinical trials with imaging being a possible
biomarker for assessing vulnerable plaque and evaluating
new therapeutic approaches in atheromatous disease. The
feasibility of combining PET and contrast enhanced MRI
opens the way to studies where these techniques can be
complementary and their utility in clinical practicecompared and cross-validated. However it needs to be
appreciated that the sample size used in this study is too
small and the results need to be validated with a larger
cohort of patients.
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